Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 646 to 660 of 717 results for diabet*

  1. Pancreatic islet cell transplantation (IPG13)

    NICE's guidance on pancreatic islet cell transplantation has now been replaced. Please go to NICE interventional procedure guidance 257 to view the full guidance on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus and to NICE interventional procedure guidance 274 to view the full guidance on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy issued to the NHS in England, Wales, Scotland and Northern Ireland.

    Interventional procedures guidance
    Published
    17 February 2003

  2. Diabetic retinopathy - ruboxistaurin [ID382]

    In development [GID-TAG386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Education and training programmes: self-management:- What is the effectiveness and cost effectiveness of education programmes to improve information and advice and to support self-management of chronic health conditions (for example, obesity, diabetes and cardiovascular disease) for people growing older with learning disabilities, and their family members and carers?

    support self-management of chronic health conditions (for example, obesity, diabetes and cardiovascular disease) for people growing...

    Research recommendation
    Published
    29 November 2018

  4. Glitazones in the treatment of type 2 diabetes (TA63)

    This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).

    Technology appraisal guidance
    Published
    27 August 2003

  5. Guidance on the use of patient-education models for diabetes (TA60)

    This guidance has been replaced by NICE guideline NG17.

    Technology appraisal guidance
    Last updated
    1 August 2015

  6. Diabetes (type 2) - rosiglitazone (TA9)

    This guidance has been replaced by NICE technology appraisal guidance 63.

    Technology appraisal guidance
    Published
    23 August 2000

  7. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)

    This guidance has been updated and replaced by NICE technology appraisal guidance 824.

    Technology appraisal guidance
    Published
    22 July 2015

  8. Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy (TA271)

    This guidance has been updated and replaced by NICE technology appraisal guidance 301.

    Technology appraisal guidance
    Published
    23 January 2013

  9. Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes (TA248)

    This guidance has been updated and replaced by NICE guideline NG28.

    Technology appraisal guidance
    Published
    22 February 2012

  10. Ranibizumab for the treatment of diabetic macular oedema (TA237)

    This guidance has been updated and replaced by NICE technology appraisal guidance 274.

    Technology appraisal guidance
    Published
    30 November 2011

  11. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

    This guidance has been updated and replaced by NICE guideline NG28.

    Technology appraisal guidance
    Last updated
    1 December 2014

  12. Diabetes (type 2) - pioglitazone (TA21)

    This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].

    Technology appraisal guidance
    Published
    27 March 2001

  13. Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine (TA53)

    This guidance has been replaced by NICE guideline NG17.

    Technology appraisal guidance
    Last updated
    1 August 2015

  14. Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

    Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

    Evidence summary
    Published
    29 January 2013

  15. Kidney conditions: CKD and SGLT2 inhibitors (IND262)

    This indicator covers the percentage of patients on the CKD register and currently treated with an ARB or an ACE inhibitor who are also currently treated with an SGLT2 inhibitor if they have either: no type 2 diabetes and a urine ACR of 22.6 mg/mmol or more, or type 2 diabetes and a urine ACR 3 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM246

    General practice indicators suitable for use outside of QOF
    Published
    21 August 2023